Oramed Pharmaceuticals Inc. (NASDAQ:ORMP - Get Free Report) saw a large growth in short interest in the month of February. As of February 15th, there was short interest totalling 576,400 shares, a growth of 149.0% from the January 31st total of 231,500 shares. Based on an average daily volume of 281,000 shares, the days-to-cover ratio is currently 2.1 days.
Wall Street Analysts Forecast Growth
Separately, StockNews.com cut Oramed Pharmaceuticals from a "hold" rating to a "sell" rating in a report on Wednesday, February 19th.
Check Out Our Latest Report on ORMP
Oramed Pharmaceuticals Price Performance
Shares of Oramed Pharmaceuticals stock traded up $0.14 on Tuesday, reaching $2.14. The company had a trading volume of 385,268 shares, compared to its average volume of 159,857. The firm has a market cap of $86.27 million, a price-to-earnings ratio of 19.45 and a beta of 1.66. The firm's 50-day moving average price is $2.29 and its two-hundred day moving average price is $2.35. Oramed Pharmaceuticals has a 1 year low of $1.96 and a 1 year high of $3.29.
Hedge Funds Weigh In On Oramed Pharmaceuticals
Institutional investors and hedge funds have recently modified their holdings of the stock. BML Capital Management LLC boosted its holdings in shares of Oramed Pharmaceuticals by 62.1% in the 3rd quarter. BML Capital Management LLC now owns 2,186,191 shares of the biotechnology company's stock worth $5,334,000 after purchasing an additional 837,153 shares during the period. Peapod Lane Capital LLC purchased a new position in Oramed Pharmaceuticals during the 4th quarter valued at $550,000. Connor Clark & Lunn Investment Management Ltd. purchased a new position in Oramed Pharmaceuticals during the 3rd quarter valued at $272,000. XTX Topco Ltd boosted its holdings in Oramed Pharmaceuticals by 59.7% during the 3rd quarter. XTX Topco Ltd now owns 24,716 shares of the biotechnology company's stock valued at $60,000 after acquiring an additional 9,242 shares during the period. Finally, Marquette Asset Management LLC purchased a new position in Oramed Pharmaceuticals during the 4th quarter valued at $81,000. Hedge funds and other institutional investors own 12.73% of the company's stock.
About Oramed Pharmaceuticals
(
Get Free Report)
Oramed Pharmaceuticals Inc engages in the research and development of pharmaceutical solutions for the treatment of diabetes and for the use of orally ingestible capsules for delivery of polypeptides. The company's product portfolio includes ORMD-0801, an oral insulin capsule, which is in phase III clinical trial for the treatment of individuals with diabetes, as well as in phase II clinical trial for the treatment of non-alcoholic steatohepatitis; and ORA-D-013-1 and ORA-D-013-2, which have completed phase II clinical trial for the treatment of type 2 diabetes.
See Also
Before you consider Oramed Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Oramed Pharmaceuticals wasn't on the list.
While Oramed Pharmaceuticals currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
